Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus


Incyte Corporation INCY is withdrawing the New Drug Application for parsaclisib in relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). 

  • Parsaclisib is the Company's next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ).
  • The decision impacts only the FL, MZL, and MCL indications in the U.S. and does not affect other ongoing clinical trials in the U.S. or other countries.
  • Related: Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US.
  • The decision to withdraw the NDA follows discussions with the FDA regarding confirmatory studies to support accelerated approval.
  • Incyte said that it could not complete the required studies within a time period to support the investment. 
  • The withdrawal is a business decision and not related to any changes in either the efficacy or safety of parsaclisib. 
  • Additionally, Incyte has opted out of its ex-U.S. development of MCLA-145, restoring full global rights to Merus NV MRUS
  • MCLA-145 is a CD137/PD-L1 bispecific antibody co-developed under a global collaboration and license agreement between Incyte and Merus.
  • Price Action: INCY stock closed at $74.15, while MRUS shares closed at $26.31 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!